IP Library › Granted Patent US 12,339,288
Granted Patent B2
US 12,339,288 · App. 17/982,769 · Granted Jun 24, 2025

Multi-protein biomarker assay for brain injury detection and outcome

Inventors: Allen D. Everett (Baltimore, MD); Jennifer E. Van Eyk (Baltimore, MD); Frederick Korley (Baltimore, MD)
Assignee: The Johns Hopkins University
G01N33/6893C12Q1/6883C12Q2600/158G01N2333/4727G01N2333/70525G01N2333/825G01N2333/988G01N2800/28G01N2800/2871
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,339,288
App. No.
17/982,769
Granted
Jun 24, 2025
Kind
B2
Abstract

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

Claims (28)

1. A method of detecting protein biomarkers in a sample obtained from a patient having or at risk of having traumatic brain injury (TBI) and/or concussion, the method comprising:

(a) performing an assay comprising detecting brain derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP), and one or both of neuron specific enolase (NSE) and neurogranin (NRGN) protein biomarkers in a biological sample obtained from the patient;

(b) measuring the levels of the protein biomarkers in the patient sample relative to the levels of the respective protein biomarkers in one or both of a non-TBI reference control or a non-concussion reference control;

(c) measuring no decrease in the level of the BDNF protein biomarker in the sample relative to the level in the one or both reference controls; and/or measuring no increase in the levels of the GFAP, NSE, and/or NRGN protein biomarkers relative to the levels in the one or both reference controls; and

(d) returning the patient to play or to work immediately based on step (c).

2. The method of claim 1 , wherein the patient has or is at risk of having short or long term post-concussive symptoms or disability after TBI.

3. The method of claim 1 , wherein the biological sample is selected from the group consisting of blood, plasma, serum, or cerebrospinal fluid (CSF).

4. The method of claim 1 , wherein the assay comprises mass spectrometry or an immunoassay selected from an enzyme linked immunosorbent assay (ELISA), a chemiluminescence-based immunoassay, or a fluorescence-based immunoassay.

5. The method of claim 1 , wherein at least one of the protein biomarkers is methylated, citrullinated, glycosylated, acetylated, or phosphorylated.

6. The method of claim 1 , further comprising detecting in the patient's sample one or more of myelin basic protein (MBP), PAD-2, tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factor1-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2 Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3); carnosine dipeptidase 1 (CNDP1); ERMIN; glutamate receptor metabotropic 3 (GRM3); kelch-like protein 32 (KLH32); melanoma antigen family E,2 (MAGE2); Metallothionein 3 (MT3), neuregulin 3 (NRG3); oligodendrocyte myelin glycoprotein (OMG); solute carrier family 39 (zinc transporter); reticulon 1 (RTN1); and peptidylarginine deiminase (types 1-4 and 6) (PAD).

7. The method of claim 1 , wherein the non-TBI reference control or the non-concussion reference control comprises a non-TBI control sample or a non-concussion control sample.

8. The method of claim 1 , wherein the assay comprises one or more capture agents selected from the group consisting of a peptide, an aptamer, and a small organic molecule that specifically binds to one or more of the protein biomarkers.

9. The method of claim 6 , wherein the assay comprises one or more capture agents selected from the group consisting of a peptide, an aptamer, and a small organic molecule that specifically binds to one or more of the protein biomarkers.

10. A method of managing patient treatment for traumatic brain injury (TBI) and/or concussion, the method comprising:

(a) obtaining a biological sample from a patient;

(b) performing an assay comprising detecting brain derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP), and one or both of neuron specific enolase (NSE) and neurogranin (NRGN) protein biomarkers in the biological sample by using a detection method selected from the group consisting of an immunoassay, mass spectroscopy, polymerase chain reaction, biochip assay, electrochemical voltammetry, amperometry, atomic force microscopy, radio frequency techniques, multipolar resonance spectroscopy, microscopy, confocal microscopy, non-confocal microscopy, surface plasmon resonance, ellipsometry, resonant mirror technique, a grating coupler waveguide technique, and interferometry;

(c) measuring the levels of protein biomarkers in the patient sample relative to the levels of the respective protein biomarkers in one or both of a non-TBI reference control or a non-concussion reference control;

(d) measuring a decreased level of BDNF in the sample compared to the level in the one or both reference controls, and/or measuring increased levels of the GFAP, NSE and/or NRGN protein biomarkers in the sample relative to the levels of the respective biomarkers in the one or both reference controls; and

(e) administering a brain injury therapy regimen to the patient based on step (d), thereby managing patient treatment for TBI and/or concussion.

11. The method of claim 10 , wherein the biological sample is selected from the group consisting of blood, plasma, serum, or cerebrospinal fluid (CSF).

12. The method of claim 10 , wherein the immunoassay is an enzyme linked immunosorbent assay (ELISA), a chemiluminescence-based immunoassay, or a fluorescence-based immunoassay.

13. The method of claim 10 , further wherein the patient has or is at risk of having concussive brain injury, intracerebral hemorrhage (ICH), short or long-term post-concussive symptoms, or disability after traumatic brain injury (TBI).

14. The method of claim 10 , further comprising detecting in the patient's sample one or more of myelin basic protein (MBP), PAD-2, tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factor1-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2 Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3); carnosine dipeptidase 1 (CNDP1); ERMIN; glutamate receptor metabotropic 3 (GRM3); kelch-like protein 32 (KLH32); melanoma antigen family E,2 (MAGE2); Metallothionein 3 (MT3) neuregulin 3 (NRG3); oligodendrocyte myelin glycoprotein (OMG); solute carrier family 39 (zinc transporter); reticulon 1 (RTN1); and peptidylarginine deiminase (types 1-4 and 6) (PAD).

15. The method of claim 10 , wherein the reference control comprises a control sample or reference level.

16. The method of claim 10 , wherein the assay comprises one or more capture agents selected from the group consisting of a peptide, an aptamer, and a small organic molecule that specifically binds to one or more of the protein biomarkers.

17. The method of claim 14 , wherein the assay comprises one or more capture agents selected from the group consisting of a peptide, an aptamer, and a small organic molecule that specifically binds to one or more of the protein biomarkers.

18. The method of claim 10 , wherein the biochip assay comprises a capture reagent selected from an adsorbent or affinity reagent.

19. The method of claim 14 , wherein the biochip assay comprises a capture reagent selected from an adsorbent or affinity reagent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: EVERETT, ALLEN D.; VAN EYK, JENNIFER E.; KORLEY, FREDERICK
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 067760/0453 →
Continuity (4)
Continuation 16713425 · Dec 13, 2019
Division 14905312
Provisional Application 61847213 · Jul 17, 2013
Related Publication 20230077876A1 · Mar 16, 2023
References Cited (149)
US 6780606B1 · Jackowski · 2004 [cited by applicant]
US 6884591B2 · Janigro et al. · 2005 [cited by applicant]
US 7144708B2 · Janigro et al. · 2006 [cited by applicant]
US 7396654B2 · Hayes et al. · 2008 [cited by applicant]
US 7427490B2 · Valkirs et al. · 2008 [cited by applicant]
US 7456027B2 · Wang et al. · 2008 [cited by applicant]
US 8460888B2 · Lafaye et al. · 2013 [cited by applicant]
US 8492107B2 · Wang et al. · 2013 [cited by applicant]
US 8557526B2 · Ottens et al. · 2013 [cited by applicant]
US 8663911B2 · Vojdani · 2014 [cited by applicant]
US 9194867B2 · Vojdani · 2015 [cited by applicant]
US 9547014B2 · Travis et al. · 2017 [cited by applicant]
US 9810698B2 · Wang et al. · 2017 [cited by applicant]
US 10041959B2 · Wang et al. · 2018 [cited by applicant]
US 10534003B2 · Everett et al. · 2020 [cited by applicant]
US 11499982B2 · Everett · 2022 [cited by examiner]
US 20030077590A1 · Pedersen et al. · 2003 [cited by applicant]
US 20030224460A1 · Pedersen et al. · 2003 [cited by applicant]
US 20060257943A1 · Dambinova · 2006 [cited by applicant]
US 20070098728A1 · Pedersen et al. · 2007 [cited by applicant]
US 20080026485A1 · Hueber et al. · 2008 [cited by applicant]
US 20080131881A1 · Ladenson et al. · 2008 [cited by applicant]
US 20080220013A1 · Hochstrasser et al. · 2008 [cited by applicant]
US 20090068691A1 · Dave et al. · 2009 [cited by applicant]
US 20110082203A1 · Wang et al. · 2011 [cited by applicant]
US 20110207126A1 · Popko et al. · 2011 [cited by applicant]
US 20130252834A1 · Dayon et al. · 2013 [cited by applicant]
US 20140045713A1 · Everett et al. · 2014 [cited by applicant]
US 20140303041A1 · Hayes et al. · 2014 [cited by applicant]
US 20140342381A1 · Hayes · 2014 [cited by applicant]
US 20150118218A1 · Travis et al. · 2015 [cited by applicant]
US 20150119273A1 · Goldstein et al. · 2015 [cited by applicant]
US 20150141528A1 · Larner · 2015 [cited by applicant]
US 20150247867A1 · Curdt et al. · 2015 [cited by applicant]
US 20150268252A1 · Svetlov et al. · 2015 [cited by applicant]
US 20160178643A1 · Everett et al. · 2016 [cited by applicant]
US 20190064187A1 · Svetlov et al. · 2019 [cited by applicant]
US 20200116739A1 · Everett et al. · 2020 [cited by applicant]
EP 2628013A2 · 2013 [cited by applicant]
EP 2707389A2 · 2014 [cited by applicant]
JP 2012530907A · 2012 [cited by applicant]
WO 2003016910A1 · 2003 [cited by applicant]
WO 2003059272A2 · 2003 [cited by applicant]
WO 2004059293A2 · 2004 [cited by applicant]
WO 2006012351A2 · 2006 [cited by applicant]
WO 2008046509A1 · 2008 [cited by applicant]
WO 2009143519A2 · 2009 [cited by applicant]
WO 2010019553A2 · 2010 [cited by applicant]
WO 2010148391A2 · 2010 [cited by applicant]
WO 2011032155A2 · 2011 [cited by applicant]
WO 2012051519A2 · 2012 [cited by applicant]
WO 2012155134A2 · 2012 [cited by applicant]
WO 2015009907A1 · 2015 [cited by applicant]
WO 2015066211A1 · 2015 [cited by applicant]
Office Action dated Mar. 30, 2023 in European Patent Application No. 20191259.9 (11 pages). [cited by applicant]
McBride et al., “Alcohol Effects on Central Nervous System Gene Expression in Genetic Animal Models,” Alcoholism: Clinical & Experimental Research, Feb. 2005, vol. 29, No. 2, pp. 167-175. [cited by applicant]
McMahon et al., “Measurement of the Glial Fibrillary Acidic Protein and Its Breakdown Products GFAP-BDP Biomarker for the Detection of Traumatic Brain Injury Compared to Computed Tomography and Magnetic Resonance Imagin… [cited by applicant]
Metting et al., “GFAP and S100B in the acute phase of mild traumatic brain injury,” Neurology, May 1, 2012, vol. 78, pp. 1428-1433. [cited by applicant]
Merck, “product 07-425,” accessed on May 26, 2015 from <www.merckmillipore.com>. [cited by applicant]
Millipore Sigma, “Anti-Neurogranin Antibody,” Millipore/Sigma (07-425) product information <www.emdmillipore.com/us>. [cited by applicant]
Mondello et al., “Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury,” Journal of Neurotrauma, Apr. 2012, vol. 29, No. 6, pp. 1096-1104. [cited by applicant]
Mondello et al., “Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study,” Critical Care, Jun. 2011, vol.… [cited by applicant]
Nagamoto-Combs et al., “Prolonged Microgliosis in the Rhesus Monkey Central Nervous System after Traumatic Brain Injury,” Journal of Neurotrauma, Nov. 2007, vol. 24, No. 11, pp. 1719-1742. [cited by applicant]
Neuner-Jehle et al., “Sleep deprivation differentially alters the mRNA and protein levels of neurogranin in rat brain,” Brain Research, 1995, vol. 685, Nos. 1-2, pp. 143-153. [cited by applicant]
Newcombe et al., “Distribution of Glial Fibrillary Acidic Protein in Gliosed Human White Matter,” Journal of Neurochemistry, 1986, vol. 47, pp. 1713-1719. [cited by applicant]
NCBI GenBank Accession No. NP_006167, Jan. 14, 2011. [cited by applicant]
Rodrigues et al., “Increased serum brain derived neurotrophic factor (BDNF) following isolated severe traumatic brain injury in humans,” Brain Injury, 2008, vol. 22, Suppl. 1, p. 165. [cited by applicant]
Rohn et al., “Caspase-Cleaved Glial Fibrillary Acidic Protein within Cerebellar White Matter of the Alzheimer's Disease Brain,” International Journal of Clinical & Experimental Pathology, 2013, vol. 6, No. 1, pp. 41-48. [cited by applicant]
Rostami et al., “Alteration in BDNF and its receptors, full-length and truncated TrkB and p75NTR following penetrating traumatic brain injury,” Brain Research, 2014, vol. 1542, pp. 195-205. [cited by applicant]
Rostami et al., “Proteomic based identification of injury-specific patterns of biomarkers following different types of TBI,” Abstracts of the Annual Meeting of the Society for Neuroscience, Society for Neuroscience, Jan… [cited by applicant]
Savage et al., “Glial Fibrillary Acidic Protein as a Plasma Biomarker of Brain Injury in Children with Sickle Cell Disease,” Blood, Nov. 20, 2009, vol. 114, No. 22, Abstract 1512. [cited by applicant]
Savage et al., “Plasma glial fibrillary acidic protein levels in children with sickle cell disease,” American Journal of Hematology, 2011, vol. 86, No. 5, pp. 427-429. [cited by applicant]
Schober et al., “Developmental traumatic brain injury decreased brain derived neurotrophic factor expression late after injury,” Metabolic Brain Disease, 2012, vol. 27, No. 2, pp. 167-173. [cited by applicant]
Shen et al., “Addressing the Needs of Traumatic Brain Injury with Clinical Proteomics,” Clinical Proteomics, 2014, vol. 11, Article No. 11, pp. 1-13. [cited by applicant]
Tang et al., “Attenuation of opioid tolerance by antisense oligodeoxynucleotides targeting neurogranin,” European Journal of Pharmacology, 2006, vol. 542, pp. 106-107. [cited by applicant]
Tang et al., “Disruption of acute opioid dependence by antisense oligodeoxynucleotides targeting neurogranin,” Brain Research, 2007, vol. 1143, pp. 78-82. [cited by applicant]
Thorsell et al., “Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease,” Brain Research, 2010, vol. 1362, pp. 13-22. [cited by applicant]
Tok et al., “Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin,” Chemical Communications, Mar. 18, 2008, pp. 1883-1885. [cited by applicant]
Vazquez et al., “Creatine Kinase BB and Neuron-Specific Enolase in Cerebrospinal Fluid in the Diagnosis of Brain Insult,” The American Journal of Forensic Medicine and Pathology, 1995, vol. 16, No. 3, pp. 210-214. [cited by applicant]
Vendt et al., “Silent Cerebral Infarct Transfusion (SIT) Trial Imaging Core: Application of Novel Imaging Information Technology for Rapid and Central Review of MRI of the Brain,” Journal of Digital Imaging, Jun. 2009, … [cited by applicant]
Vos et al., “Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury,” Neurology, Apr. 2004, vol. 62, No. 8, pp. 1303-1310. [cited by applicant]
Wang et al., “MRI Abnormalities of the Brain in One-Year-Old Children With Sickle Cell Anemia,” Pediatric Blood & Cancer, Nov. 2008, vol. 51, No. 5, pp. 643-646. [cited by applicant]
Watson et al., “Localization of RC3 (neurogranin) in rat brain subcellular fractions,” Molecular Brain Research, 1994, vol. 27, No. 2, pp. 323-328. [cited by applicant]
Williams et al., “Proteomic-Based Approach for Biomarker Discovery to Predict Silent Cerebral Infarct in Patients with Sickle Cell Disease,” 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 20… [cited by applicant]
Wu et al., “Characterization, using comparative proteomics, of differentially expressed proteins in the hippocampus of the mesial temporal lobe of epileptic rats following treatment with valproate,” Amino Acids, 2011, v… [cited by applicant]
Yang et al., “Glial Fibrillary Acidic Protein: from Intermediate Filament Assembly and Gliosis to Neurobiomarker,” Trends in Neurosciences, Jun. 2015, vol. 38, No. 6, pp. 364-374. [cited by applicant]
Yang et al., “Serum Neurogranin Measurement as a Biomarker of Acute Traumatic Brain Injury,” Clinical Biochemistry, 2015, vol. 48, Nos. 13-14, pp. 843-848. [cited by applicant]
Zetterberg et al., “Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood,” Nature Reviews Neurology, Apr. 2013, vol. 9, pp. 201-210. [cited by applicant]
Zetterberg et al., “Neurochemical Aftermath of Amateur Boxing,” Archives of Neurology, Sep. 2006, vol. 63, pp. 1277-1280. [cited by applicant]
Zetterberg et al., “Sustained release of neuron-specific enolase to serum in amateur boxers,” Brain Injury, 2009, vol. 23, No. 9, pp. 723-726. [cited by applicant]
Zhang et al., “Human Traumatic Brain Injury Induces Autoantibody Response Against Glial Fibrillary Acidic Protein and Its Breakdown Products,” PLoS One, Mar. 2014, vol. 9, No. 3, e92698, pp. 1-16. [cited by applicant]
Zhang et al., “Methods for Peptide and Protein Quantification by Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry,” Molecular & Cellular Proteomics, 2011, pp. 1-62. [cited by applicant]
Zoltewicz et al., “Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury,” Biomarker Insights, 2012, vol. 7, pp. 71-79. [cited by applicant]
Extended European Search Report dated Feb. 10, 2014 in European Patent Application No. 11833480. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 6, 2014 in corresponding International PCT Patent Application No. PCT/US2014/046986 (12 pages). [cited by applicant]
European Search Report dated Jul. 13, 2015 in European Patent Application No. 12782967. [cited by applicant]
European Search Report dated Oct. 9, 2015 in European Patent Application No. 13760865. [cited by applicant]
Extended European Search Report dated Apr. 18, 2017 in corresponding European Patent Application No. 148267867.7 (20 pages). [cited by applicant]
Examination Report dated Apr. 6, 2018 in corresponding European Patent Application No. 14826786.7 (5 pages). [cited by applicant]
English translation of the Office Action dated Jul. 26, 2018 in corresponding Japanese Patent Application No. 2016-527092 (3 pages). [cited by applicant]
Office Action dated Jan. 14, 2019 in corresponding European Patent Application No. 14826786.7 (8 pages). [cited by applicant]
English translation of the Office Action dated Feb. 6, 2019 in corresponding Japanese Patent Application No. 2016-527092 (2 pages). [cited by applicant]
English translation of the Office Action dated Mar. 11, 2019 in corresponding Israeli Patent Application No. 243393 (2 pages). [cited by applicant]
Decision to Refuse dated Jun. 10, 2020 in corresponding European Patent Application No. 14826786.7 (11 pages). [cited by applicant]
Office Action dated Sep. 16, 2020 in corresponding Japanese Patent Application No. 2019-195925 (4 pages). [cited by applicant]
English translation of the Office Action dated Sep. 16, 2020 in corresponding Japanese Patent Application No. 2019-195925 (4 pages). [cited by applicant]
Partial European Search Report dated Nov. 16, 2020 in corresponding European Patent Application No. 20191259.9 (24 pages). [cited by applicant]
Extended European Search Report dated Apr. 9, 2021 in corresponding European Patent Application No. 20191259.9 (24 pages). [cited by applicant]
Office Action dated Jun. 8, 2021 in corresponding Japanese Patent Application No. 2019-195925 (2 pages). [cited by applicant]
English translation of the Office Action dated Jun. 8, 2021 in corresponding Japanese Patent Application No. 2019-195925 (1 page). [cited by applicant]
Babcock et al., “Ability of S100B to predict severity and cranial CT results in children with TBI,” Brain Injury, Oct. 2012, vol. 26, No. 11, pp. 1372-1380. [cited by applicant]
Berger et al., “Multiplex Assessment of Serum Biomarker Concentrations in Well-Appearing Children With Inflicted Traumatic Brain Injury,” Pediatric Research, 2009, vol. 65, No. 1, pp. 97-102. [cited by applicant]
Berger et al., “The Use of Biomarkers After Inflicted Traumatic Brain Injury: Insight into Etiology, Pathophysiology, and Biochemistry,” Clinical Pediatric Emergency Medicine, 2006, vol. 7, pp. 186-193. [cited by applicant]
Biberthaler et al., “Serum S-100B Concentration Provides Additional Information For the Indication of Computed Tomography in Patients After Minor Head Injury: A Prospective Multicenter Study,” Shock, May 2006, vol. 25, … [cited by applicant]
Buki et al., “Minor and Repetitive Head Injury,” Advances and Technical Standards in Neurosurgery, 2015, vol. 42, pp. 147-192. [cited by applicant]
Clayton et al., “Conservation and Expression of IQ-Domain-Containing Calpacitin Gene Products (Neuromodulin/GAP-43, Neurogranin/RC3) in the Adult and Developing Oscine Song Control System,” Developmental Neurobiology, 2… [cited by applicant]
Feala et al., “Systems Biology Approaches for Discovering Biomarkers for Traumatic Brain Injury,” Journal of Neurotrauma, Jul. 1, 2013, vol. 30, No. 13, pp. 1101-1116. [cited by applicant]
Griesbach et al., “Alterations in BDNF and Synapsin I within the Occipital Cortex and Hippocampus after Mild Traumatic Brain Injury in the Developing Rat: Reflections of Injury-Induced Neuroplasticity,” Journal of Neuro… [cited by applicant]
Haqqani et al., “Biomarkers and Diagnosis: Protein Biomarkers in Serum of Pediatric Patients with Severe Traumatic Brain Injury Identified by ICAT-LC-MS/MS,” Journal of Neurotrauma, 2007, vol. 24, No. 1, pp. 54-74. [cited by applicant]
Hiergenroeder et al., “Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury,” Molecular Diagnosis & Therapy, 2008, vol. 12, No. 6, pp. 345-358. [cited by applicant]
Hoehna et al., “Matrix metalloproteinase 9 regulates cell death following pilocarpine-induced seizures in the developing brain,” Neurobiology of Disease, 2012, vol. 48, pp. 339-347. [cited by applicant]
Hoshi et al., “Relations of Serum High-Sensitivity C-Reactive Protein and Interleukin-6 Levels With Silent Brain Infarction,” Stroke, 2005, vol. 36, No. 4, pp. 768-772. [cited by applicant]
Ichkova et al., “New Biomarker Stars for Traumatic Brain Injury,” Journal of Cerebral Blood Flow & Metabolism, 2017, vol. 37, No. 10, pp. 3276-3277. [cited by applicant]
Iliuk et al., “Aptamer in Bioanalytical Applications,” Analytical Chemistry, 2011, vol. 83, pp. 4440-4452. [cited by applicant]
Ingebrigtsen et al., “The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study,” Brain Injury, 2000, vol. 14, No. 12, pp. 1047-1055. [cited by applicant]
Ishigami et al., “Abnormal Accumulation of Citrullinated Proteins Catalyzed by Peptidylarginine Deiminase in Hippocampal Extracts From Patients With Alzheimer's Disease,” Journal of Neuroscience Research, 2005, vol. 80,… [cited by applicant]
Jeter et al., “Biomarkers for the Diagnosis and Prognosis of Mild Traumatic Brain Injury/Concussion,” Journal of Neurotrauma, Apr. 2013, vol. 30, No. 8, pp. 657-670. [cited by applicant]
Kazanis et al., “Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration,” Experimental Neurology, 2004, vol. 186, No. 2, pp. 221-234. [cited by applicant]
Ke et al., “Increased Expression of Small Heat Shock Protein αB-Crystallin After Intracerebral Hemorrhage in Adult Rats,” Journal of Molecular Neuroscience, 2013, vol. 51, pp. 159-169. [cited by applicant]
Khan et al., “S-Nitrosoglutathione reduced oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats,” Journal of Neuroinflammation, Jul. 6, 2011, vol. 8, Article No. 78, pp. 1-18. [cited by applicant]
Korley et al., “Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury,” Journal of Neurotrauma, Jan. 2016, vol. 33, No. 2, pp. 215-225. [cited by applicant]
Koumura et al., “Metallothionein-3 deficient mice exhibit abnormalities of psychological behaviors,” Neuroscience Letters, 2009, vol. 467, pp. 11-14. [cited by applicant]
Lange et al., “Evaluation of Eight Plasma Proteins as Candidate Blood-Based Biomarkers for Malignant Gliomas,” Cancer Investigation, 2014, vol. 32, pp. 423-429. [cited by applicant]
Laterza et al., “Biomarkers of tissue injury,” Biomarkers in Medicine, 2008, vol. 2, No. 1, pp. 81-92. [cited by applicant]
Laterza et al., “Identification of Novel Brain Biomarkers,” Clinical Chemistry, 2006, vol. 52, No. 9, pp. 1713-1721. [cited by applicant]
Lumpkins et al., “Glial Fibrillary Acidic Protein is Highly Correlated with Brain Injury,” The Journal of Trauma and Acute Care Surgery, Oct. 2008, vol. 65, No. 4, pp. 778-784. [cited by applicant]
Martinez et al., “Type-Dependent Oxidative Damage in Frontotemporal Lobar Degeneration: Cortical Astrocytes are Targets of Oxidative Damage,” Journal of Neuropathology & Experimental Neurology, Dec. 2008, vol. 67, No. 1… [cited by applicant]
Nylen et al., “Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome,” Journal of the Neurological Sciences, 2006, vol. 240, Nos. 1-2, pp. 85-91. [cited by applicant]
Oguz et al., “Assessment of Citrullinated Myelin by 1H-MR Spectroscopy in Early-Onset Multiple Sclerosis,” American Journal of Neuroradiology, 2009, vol. 30, No. 4, pp. 716-721. [cited by applicant]
Okonkwo et al., “GFAP-BDP as an Acute Diagnostic Marker in Traumatic Brain Injury: Results from the Prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study,” Journal of Neurotrauma, Sep.… [cited by applicant]
Oliveira et al., “Outcome biomarkers following severe traumatic brain injury,” Revista Brasileira de Terapia Intensiva, 2008, vol. 20, No. 4, pp. 411-421. [cited by applicant]
Ottens et al., “Neuroproteomics in Neurotrauma,” Mass Spectrometry Reviews, 2006, vol. 25, No. 3, pp. 380-408. [cited by applicant]
Pak et al., “Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: A study with knockout mice,” Proceedings of the National Academy of… [cited by applicant]
Papa et al., “Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated with Intracranial Lesions and Neurosurgical Intervention,” Annals of E… [cited by applicant]
Papa et al., “Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions a… [cited by applicant]
Pegelow et al., “Silent Infarcts in Children With Sickle Cell Anemia and Abnormal Cerebral Artery Velocity,” Archives of Neurology, Dec. 2001, vol. 58, No. 12, pp. 2017-2021. [cited by applicant]
Pelinka et al., “GFAP Versus S100B in Serum after Traumatic Brain Injury: Relationship to Brain Damage and Outcome,” Journal of Neurotrauma, 2004, vol. 21, No. 11, pp. 1553-1561. [cited by applicant]
Pelinka et al., “Glial Fibrillary Acidic Protein in Serum After Traumatic Brain Injury and Multiple Trauma,” The Journal of Trauma and Acute Care Surgery, Nov. 2004, vol. 57, pp. 1006-1012. [cited by applicant]
Radka et al., “Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay,” Brain Research, 1996, vol. 709, pp. 122-130. [cited by applicant]